Volumen: 20 # Number : 2
Publication Date : Mayo - Agosto Year: 2016
Authors: Rivas M M
Abstract: Advances in immunotherapy have led to the development
of therapies that enhance the action of T
cells against tumor cells. Blinatumomab is a firstin-
class bispecific T-cell engager (BiTE) that binds
to both CD19 of B-cells and CD3 of T-cells. Even
though the first clinical trials have been done in patients
with non Hodgkin lymphoma, the great impact
has been seen in patients with acute lymphoblastic
leukemia. A pivotal phase II trial demonstrated that
response rates were high in a refractory or relapsed
patient population, with 43% achieving complete
remission (CR). Median overall survival was 6.1
months. These results have led to the FDA approval
of blinatumomab in this patient population. Most
relevant toxicities include neurologic events and cytokine
release syndrome, both reversible after infusion
suspension. Is the aim of this presentation, to
summarize the development and characteristics of
this new type of therapy.
Key words: blinatumumab,
bispecific t cell engager
BITE
Pages :
|
